PedAM
Pediatric Disease Annotations & Medicines
| erythema multiforme | ||||
| Disease ID | 377 |
|---|---|
| Disease | erythema multiforme |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:9) HP:0010783 | Erythema | 5 HP:0001025 | Hives | 1 HP:0001019 | Exfoliative dermititis | 1 HP:0100522 | Thymoma | 1 HP:0003002 | Breast carcinoma | 1 HP:0001945 | Fever | 1 HP:0001875 | Neutropenia | 1 HP:0001880 | Eosinophilia | 1 HP:0002725 | Systemic lupus erythematosus | 1 |
| Disease ID | 377 |
|---|---|
| Disease | erythema multiforme |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:13) C2364133 | infection C0524702 | pulmonary thromboembolism C0409974 | lupus erythematosus C0263591 | drug-induced lupus erythematosus C0153042 | herpetic whitlow C0149745 | oral ulceration C0085074 | granuloma annulare C0042769 | virus infection C0037284 | skin lesions C0029166 | oral manifestations C0019348 | herpes simplex C0014518 | toxic epidermal necrolysis C0011609 | drug eruption |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:5) C0009450 | infection | 5 C0409974 | lupus erythematosus | 4 C0019348 | herpes simplex | 3 C0042769 | virus infection | 2 C0037284 | skin lesions | 2 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:11) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0014742 | ampicillin | D000667 | 69-53-4 | erythema multiforme | MESH:D004892 | marker/mechanism | 7919560 | ||
| C0014742 | azithromycin | D017963 | 83905-01-5 | erythema multiforme | MESH:D004892 | marker/mechanism | 19421963 | ||
| C0014742 | cladribine | D017338 | 4291-63-8 | erythema multiforme | MESH:D004892 | marker/mechanism | 10792402 | ||
| C0014742 | ciprofloxacin | D002939 | 85721-33-1 | erythema multiforme | MESH:D004892 | marker/mechanism | 2222106 | ||
| C0014742 | dapsone | D003622 | 80-08-0 | erythema multiforme | MESH:D004892 | marker/mechanism | 6231576 | ||
| C0014742 | lidocaine | D008012 | 137-58-6 | erythema multiforme | MESH:D004892 | marker/mechanism | 18073329 | ||
| C0014742 | paclitaxel | D017239 | - | erythema multiforme | MESH:D004892 | marker/mechanism | 12582404 | ||
| C0014742 | phenytoin | D010672 | 57-41-0 | erythema multiforme | MESH:D004892 | marker/mechanism | 4044332 | ||
| C0014742 | thalidomide | D013792 | 50-35-1 | erythema multiforme | MESH:D004892 | therapeutic | 2985516 | ||
| C0014742 | valproic acid | D014635 | 99-66-1 | erythema multiforme | MESH:D004892 | marker/mechanism | 19040509 | ||
| C0014742 | vancomycin | D014640 | 1404-90-6 | erythema multiforme | MESH:D004892 | marker/mechanism | 11601669 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D004892 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D004892 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D004892 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D004892 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |